Stifel analyst Annabel Samimy downgraded Prometheus to Hold from Buy with a price target of $200, up from $155, after the company agreed to be acquired by Merck (MRK) for $200 per share.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RXDX:
- Prometheus downgraded to Neutral from Buy at BTIG
- Merck Acquiring Prometheus Biosciences
- Merck acquires Prometheus Biosciences for $200 per share
- Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
- Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference